A Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous TRV250

Trevena

Status and phase: Terminated; Phase 1

Conditions: Migraines

Treatments: Drug: Part B: TRV250 Dose 1; Drug: Placebo; Drug: Part B: TRV250 Dose 2; Drug: Part B: TRV250 Dose 3; Drug: Part A: TRV250-20mg/ml

Study type: Interventional

Funder types: Industry

Identifiers

NCT04201080

CP250-1002

Details and patient eligibility

About

A trial to assess the efficacy, safety, tolerability and effect of a drug (code name TRV250) given as an injection to subjects who have received an injection of a drug called glyceryl trinitrate (GTN) which is clinically known to induce an immediate headache of short duration (under 30 minutes), known as the "GTN immediate headache"

Full description

This is a Phase 1, two-part, single dose, randomised, double-blind, placebo-controlled parallel study to evaluate the efficacy, safety, tolerability and pharmacokinetics of subcutaneous TRV250 following glyceryl trinitrate infusion-evoked migraine type headache.

Approximately 360 patients (120 in Part A and 240 in Part B) are planned to complete dosing and assessments.

Part A will be a proof of concept study; approximately 120 patients will be randomised to 1 of 2 treatments (60 patients per treatment arm). Patients will receive either TRV250 (20 mg) or placebo administered subcutaneously in a double-blind manner. Part B will be a dose-ranging study; approximately 240 patients will be randomised to 1 of 4 treatments (60 patients per treatment arm). Patients will receive 1 of 3 doses of TRV250 or placebo administered subcutaneously in a double-blind manner.

The study will consist of 3 phases: Screening, Confinement, and Follow-Up. Patients will participate in an outpatient Screening visit, a 3-day inpatient Confinement Phase that comprises GTN-infusion and treatment with TRV250 or placebo, and an outpatient safety Follow-Up visit 5 to 7 days post-dose.

The expected duration of participation is up to 6 weeks.

The diagnosis and criteria for inclusion covers male and female patients aged 18-55 years (inclusive), with a body mass index (BMI) within the range 18-32 kg/m2 inclusive at Screening. The patient must experience a migraine without aura as defined by International Headache Society (IHS) criteria 1.1 and experience between 1 migraine attack every other month to 8 migraine attacks per month. They should have had a positive outcome with Triptans, for their migraine attacks (Triptan Responders).

The investigational product (TRV250) will be administered by subcutaneous injection (10 mg/ml per injection). In Part A, 2 injections will be administered to deliver a single dose of 20 mg. In Part B, the dose levels to be administered will be decided following interim analysis of the data collected in Part A; however, the doses selected will not exceed that administered in Part A (up to 2 injections will be administered to deliver a single dose of up to 20 mg). Matched placebo injections will be administered by subcutaneous injections to maintain blinding.

By virtue of this being an exploratory study for the purpose of estimation and prediction, Bayesian estimates along with posterior predictive probabilities will be provided to address the primary and secondary efficacy objectives, as appropriate. Standard descriptive statistics will be provided to assess secondary safety and pharmacokinetic objectives.

Interim analyses will be conducted at the end of Part A of the study prior to proceeding to Part B. Preliminary pharmacokinetics (using nominal times) will be conducted to estimate the AUCt, AUC∞, Cmax, and t1/2. These preliminary efficacy, pharmacokinetic, safety and tolerability data will be evaluated unblinded at the end of Part A and shared with the Investigators in an unblinded manner, prior to starting Part B.

Once the study is complete, pharmacokinetic analyses will be completed using actual collection times.

In Part A, the difference in treatment proportions of patients who experience a headache occurring up to 4 hours post-dose will be tested using a chi-square. If the patient requires rescue medication then the patient will be considered a non-responder. In Part B, a Bayesian approach will be utilized using the prior information obtain from Part A. The proportion of patients who experience a headache occurring up to 4 hours post-dose, will be modelled using a Bayesian hierarchical logistic regression. This logistic regression will include a continuous covariate for TRV250 dose where Placebo is considered to be 0 mg of TRV250. If the patient requires rescue medication then the patient will be considered a non-responder.

Demographic and baseline data will be listed and summarised descriptively. Safety and tolerability assessments will be listed and summarised descriptively by treatment group as the observations and when appropriate, as the change from baseline. Plasma PK parameter values will be listed and summarised by treatment group. Dose proportionality may be assessed with a power model and slope analysis.

Safety laboratory tests will be tabulated and any out of range values highlighted. Clinically significant changes in safety laboratory results will be recorded as AEs.

Enrollment: 9 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient is male or female, aged between 18 and 55 years inclusive.
• Patient's Body Mass Index (BMI) is between 18 and 32 kg/m2 inclusive.
• Patient should have a clinical diagnosis of migraine without aura (IHS criteria 1.1) and experience between 1 migraine attack every other month to 8 migraine attacks per month. They should have had a positive outcome with Triptans, for their migraine attacks (Triptan Responders).

Exclusion criteria

• Patient has previous exposure to TRV250.
• Abnormal EEG at screening or risk factors of increased seizure potential, such as previous seizures, history of febrile seizures, cerebral tumor, stroke, cerebrovascular disease, or significant traumatic brain injury.
• Patient with a history of hypotension or hypertension, including where this is currently under control.
• Patient taking prophylactic migraine treatments such as beta blockers 28 days before GTN infusion on Day 1.
• Resting heart rate <45 beats per minute on assessment of vital signs at screening or pre-GTN infusion on Day 1.
• QTcF >450 msec at screening (mean of three ECGs) or pre-GTN infusion on Day 1.
• Patient with another headache disorder such as menstrual migraine, chronic migraine, cluster headache, tension headache or other chronic headache states.
• Patient who have a history, or family history of any vascular intracranial lesion such as subarachnoid aneurysm or similar and patients with a relevant neurological history.
• Patients who have any allergies/contraindications for Triptan administration.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

9 participants in 6 patient groups, including a placebo group

Part A: TRV250 for SC injection

Experimental group

Description:

2 SC injections of (10 mg/ml per injection)

Treatment:

Drug: Part A: TRV250-20mg/ml

Part A: Placebo for SC injection

Placebo Comparator group

Description:

2 SC injections (identical to the TRV250)

Treatment:

Drug: Placebo

Drug: Placebo

Part B: TRV250 dose 1 for SC injection

Experimental group

Description:

1 of 3 doses of TRV250 (using 2 identical syringes)

Treatment:

Drug: Part B: TRV250 Dose 1

Part B: TRV250 dose 2 for SC injection

Experimental group

Description:

1 of 3 doses of TRV250 (using 2 identical syringes)

Treatment:

Drug: Part B: TRV250 Dose 2

Part B: TRV250 dose 3 for SC injection

Experimental group

Description:

1 of 3 doses of TRV250 (using 2 identical syringes)

Treatment:

Drug: Part B: TRV250 Dose 3

Part B: Placebo for SC injection

Placebo Comparator group

Description:

Placebo (using syringes identical to the TRV250 arms)

Treatment:

Drug: Placebo

Drug: Placebo